The U.S. health authorities have introduced a new policy regarding hepatitis B vaccinations for newborns, suggesting that the vaccine should only be administered to those identified as at risk.
This approach has prompted serious concerns among health experts, who warn that it could lead to a significant rise in the number of infected infants.
Studies indicate that limiting the vaccine's availability may result in more cases of hepatitis B, potentially impacting public health and increasing the burden on healthcare systems.